(Q34986024)

English

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 August 2017

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). (English)

1 reference

Europe PubMed Central

5 August 2017

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

Eduard Montanya

object named as

Eduard Montanya

5

0 references

object named as

Giorgio Sesti

3

0 references

Julio Rosenstock

2

object named as

Julio Rosenstock

1 reference

Europe PubMed Central

5 August 2017

object named as

John B Buse

1

0 references

Edelmiro Menéndez Torre

1 reference

ORCID Public Data File 2021

Marcin J Zychma

7

object named as

Marcin Zychma

1 reference

Europe PubMed Central

5 August 2017

author name string

Wolfgang E Schmidt

4

1 reference

Europe PubMed Central

5 August 2017

Jason H Brett

6

1 reference

Europe PubMed Central

5 August 2017

Lawrence Blonde

8

1 reference

Europe PubMed Central

5 August 2017

LEAD-6 Study Group

9

1 reference

Europe PubMed Central

5 August 2017

language of work or name

0 references

publication date

8 June 2009

1 reference

Europe PubMed Central

5 August 2017

1 reference

Europe PubMed Central

5 August 2017

374

1 reference

Europe PubMed Central

5 August 2017

39-47

1 reference

Europe PubMed Central

5 August 2017

9683

1 reference

Europe PubMed Central

5 August 2017

Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for th

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960659-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960659-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960659-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Incretin-based therapies in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960659-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960659-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960659-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960659-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960659-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960659-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960659-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960659-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960659-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960659-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960659-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960659-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960659-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960659-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Drug-induced acute pancreatitis: an evidence-based review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960659-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960659-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): a new model for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960659-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(09)60659-0

1 reference

Europe PubMed Central

5 August 2017

1 reference

Europe PubMed Central

5 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34986024&oldid=1992306867"